C Seynaeve

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. pmc Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial
    Sepideh Saadatmand
    Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands
    BMC Cancer 12:440. 2012
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  3. pmc Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy
    Murly Bm Tan
    Department of Psychosocial Care, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Hered Cancer Clin Pract 7:6. 2009
  4. pmc Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases
    Petra E A Huijts
    Department of Clinical Genetics, K5 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Breast Cancer Res 9:R78. 2007
  5. pmc A family history of breast cancer will not predict female early onset breast cancer in a population-based setting
    Geertruida H de Bock
    Department of Epidemiology, Groningen University Medical Center, Groningen, The Netherlands
    BMC Cancer 8:203. 2008
  6. pmc Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic
    Bernadette A M Heemskerk-Gerritsen
    Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 14:3335-44. 2007
  7. ncbi request reprint Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy
    C Seynaeve
    Family Cancer Clinic, Department of Medical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, Groene Hilledijk, 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 40:1150-8. 2004
  8. ncbi request reprint Tailoring breast cancer therapy to genetic status
    Caroline Seynaeve
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, 3075 AE Rotterdam, Netherlands
    Lancet 365:1672-3. 2005
  9. ncbi request reprint Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study
    I van Oostrom
    Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Clin Genet 71:35-42. 2007
  10. ncbi request reprint Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
    C T M Brekelmans
    Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE Rotterdam, The Netherlands
    Eur J Cancer 43:867-76. 2007

Collaborators

Detail Information

Publications70

  1. pmc Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial
    Sepideh Saadatmand
    Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands
    BMC Cancer 12:440. 2012
    ..The aim of the Familial MRI Screening Study (FaMRIsc) is to compare the efficacy of MRI screening to mammography for women with a familial risk. Furthermore, we will assess the influence of breast density...
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  3. pmc Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy
    Murly Bm Tan
    Department of Psychosocial Care, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Hered Cancer Clin Pract 7:6. 2009
    ..This may help them arrive at an informed decision, to detect and manage psychological distress, and to plan psychological support services...
  4. pmc Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases
    Petra E A Huijts
    Department of Clinical Genetics, K5 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Breast Cancer Res 9:R78. 2007
    ..Seven SNPs in five genomic loci were recently found to confer a mildly increased risk of breast cancer...
  5. pmc A family history of breast cancer will not predict female early onset breast cancer in a population-based setting
    Geertruida H de Bock
    Department of Epidemiology, Groningen University Medical Center, Groningen, The Netherlands
    BMC Cancer 8:203. 2008
    ..The aim of the current study was to determine the predictive value of a family history of cancer with regard to early onset of female breast cancer in a population based setting...
  6. pmc Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic
    Bernadette A M Heemskerk-Gerritsen
    Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 14:3335-44. 2007
    ..Prophylactic mastectomy (PM) results in the greatest BC risk reduction. Long-term data on the efficacy and sequels of PM are scarce...
  7. ncbi request reprint Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy
    C Seynaeve
    Family Cancer Clinic, Department of Medical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, Groene Hilledijk, 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 40:1150-8. 2004
    ..These data suggest an indication for long-term follow up in HBC and should be taken into account when additional 'risk-reducing' surgery after primary BCT is eventually considered...
  8. ncbi request reprint Tailoring breast cancer therapy to genetic status
    Caroline Seynaeve
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, 3075 AE Rotterdam, Netherlands
    Lancet 365:1672-3. 2005
  9. ncbi request reprint Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study
    I van Oostrom
    Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Clin Genet 71:35-42. 2007
    ..Identifying individuals with insufficient sources of support and addressing the family communication concerning hereditary cancer in genetic counseling may help the counselee to adjust better to genetic testing...
  10. ncbi request reprint Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
    C T M Brekelmans
    Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE Rotterdam, The Netherlands
    Eur J Cancer 43:867-76. 2007
    ..The prognostic impact of the classical tumour and treatment factors in hereditary BC is insufficiently known...
  11. ncbi request reprint Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families
    L C Verhoog
    Division of Tumour Endocrinology, Department of Medical Oncology, Daniel den Hoed Cancer Center, University Hospital, Rotterdam, The Netherlands
    Eur J Cancer 37:2082-90. 2001
    ..Thus, large regional differences exist in the prevalence of certain specific BRCA1/BRCA2 founder mutations, even in very small areas concerning populations of approximately 200000 inhabitants...
  12. ncbi request reprint Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
    H Meijers-Heijboer
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 345:159-64. 2001
    ..2; 95 percent confidence interval, 0.4 to 3.7; P=0.80). CONCLUSIONS: In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up...
  13. doi request reprint Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis
    B A M Heemskerk-Gerritsen
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Oncol 24:2029-35. 2013
    ..To prospectively assess the efficacy of bilateral risk-reducing mastectomy (BRRM) when compared with surveillance on breast cancer (BC) risk and mortality in healthy BRCA1 and BRCA2 mutation carriers...
  14. pmc Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
    L C Verhoog
    Family Cancer Clinic, Department of Medical Oncology, Daniel den Hoed Cancer Centre, University Hospital Rotterdam, The Netherlands
    Br J Cancer 83:384-6. 2000
    ..02). These data suggest that age at diagnosis of the first tumour should be taken into account when prophylactic mastectomy in BRCA1-patients is considered...
  15. ncbi request reprint Passive coping and psychological distress in women adhering to regular breast cancer surveillance
    K Pieterse
    Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
    Psychooncology 16:851-8. 2007
    ..Coping style was not associated with the trend of psychological distress around the two surveillance appointments. It is recommendable to take coping styles into account when counselling these high-risk women...
  16. ncbi request reprint Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial
    A J ten Tije
    Department of Medical Oncology, Erasmus MC Rotterdam Cancer Institute m Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Eur J Cancer 40:352-7. 2004
    ..Weekly paclitaxel at this dose and schedule is an effective treatment regimen in the elderly patient with metastatic breast cancer, and is feasible, but yields relevant fatigue in a subset of patients...
  17. ncbi request reprint Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer
    M M A Tilanus-Linthorst
    Department of Surgical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Br J Surg 93:961-8. 2006
    ..This study investigated the influence of contralateral cancer and tumour stage on survival in patients with familial non-BRCA1/BRCA2-associated breast cancer...
  18. doi request reprint Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
    P M L H Vencken
    Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Ann Oncol 22:1346-52. 2011
    ....
  19. doi request reprint Effects of CYP induction by rifampicin on tamoxifen exposure
    L Binkhorst
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 92:62-7. 2012
    ..Given the extensive metabolism undergone by tamoxifen, several factors may have contributed to this effect. Similar drug-drug interactions may exist between tamoxifen and other strong CYP inducers...
  20. ncbi request reprint Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane
    C H Smorenburg
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Breast Cancer Res Treat 66:83-7. 2001
    ..Gemcitabine is ineffective as third-line single agent therapy in patients failing anthracycline and taxane treatment for metastatic breast cancer...
  21. ncbi request reprint Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing
    I van Oostrom
    Department of Clinical Genetics, Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
    Ann Oncol 17:1090-5. 2006
    ..This study explores the effect of age at the time of parental cancer diagnosis or death on psychological distress and cancer risk perception in individuals undergoing genetic testing for a specific cancer susceptibility...
  22. ncbi request reprint Survival and prognostic factors in BRCA1-associated breast cancer
    C T M Brekelmans
    Department of Medical Oncology, Department of Surgical Oncology and Department of Clinical Genetics, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Oncol 17:391-400. 2006
    ..Further, the prognostic impact of the classical tumour and treatment factors is unclear in BRCA1-associated BC...
  23. pmc The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
    L A Lammers
    Department of Hospital Pharmacy, Erasmus MC, University Hospital, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Br J Cancer 103:765-71. 2010
    ....
  24. ncbi request reprint Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients
    C H Smorenburg
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Anticancer Drugs 11:825-8. 2000
    ..9 months. In this study topically applied miltefosine for metastatic skin lesions of breast cancer showed modest activity in a relatively heavily pretreated patient population, without serious systemic toxicity...
  25. doi request reprint Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands
    P M L H Vencken
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Ann Oncol 24:2036-42. 2013
    ..In a nationwide cohort, we examined the results of primary treatment, progression-free survival (PFS), treatment-free interval (TFI), and OS of BRCA1 versus BRCA2 EOC patients...
  26. ncbi request reprint Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy
    P Hamberg
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, Rotterdam, The Netherlands
    Eur J Cancer 43:1514-28. 2007
    ..As in other research areas, maximal progress will be achieved by joined efforts of co-operative research groups...
  27. ncbi request reprint Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
    C T Brekelmans
    Department of Medical Oncology, Family Cancer Clinic, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 19:924-30. 2001
    ..The effectiveness of surveillance in high-risk women and especially BRCA1/2 mutation carriers is unknown. We present first results from a single large family cancer clinic...
  28. ncbi request reprint Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer
    M Kriege
    Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Centre, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 102:357-63. 2007
    ....
  29. ncbi request reprint Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study
    J G Klijn
    Department of Medical Oncology, Rotterdam Cancer Institute, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 92:903-11. 2000
    ....
  30. ncbi request reprint Primitive neuroectodermal tumor of the cervix uteri: a case report -- changing concepts in therapy
    A Snijders-Keilholz
    Erasmus University Medical Center, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands
    Gynecol Oncol 98:516-9. 2005
    ..The treatment policies in these eight cases differed considerably, partly due to the rarity of the disease and to differing time periods of diagnosis and treatment...
  31. ncbi request reprint The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy
    P J C Bresser
    Department of Medical Psychology and Psychotherapy, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Eur J Cancer 43:95-103. 2007
    ..More research is needed to further define the characteristics of the women who continue to have clinically relevant increased scores after surgery, in order to offer them additional counselling...
  32. ncbi request reprint Women's acceptance of MRI in breast cancer surveillance because of a familial or genetic predisposition
    M L Essink-Bot
    Department of Public Health, Erasmus MC University Medical Center Rotterdam, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast 15:673-6. 2006
    ..MRI provided the most reassurance of breast cancer being absent in case of a favourable test result. MRI seems to be acceptable as a screening test for women at increased breast cancer risk and is preferred by them over mammography...
  33. doi request reprint The Distress Thermometer assessed in women at risk of developing hereditary breast cancer
    S Van Dooren
    Department of Medical Psychology and Psychotherapy, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    Psychooncology 18:1080-7. 2009
    ..Further, the women filled in an evaluation form...
  34. ncbi request reprint [Preventive surgical prcedures for inherited risk of breast cancer]
    M B E Menke-Pluymers
    Erasmus MC Daniel den Hoed Oncologisch Centrum, Postbus 5201, 3008 AE Rotterdam
    Ned Tijdschr Geneeskd 149:2663-7. 2005
    ..The complexity of the problem demands a multidisciplinary approach within the context of a family cancer clinic...
  35. pmc Impact of screening for breast cancer in high-risk women on health-related quality of life
    A J Rijnsburger
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Br J Cancer 91:69-76. 2004
    ..In this study, high-risk women who opted for regular breast cancer screening had a better health status than women from the general population...
  36. pmc A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance
    J Verweij
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, The Netherlands
    Br J Cancer 64:361-4. 1991
    ..Epidoxorubicin toxicities were as expected but the frequency of severe leucocytopenia was striking. This treatment schedule can not be considered active in colorectal cancer...
  37. ncbi request reprint Novel endocrine therapies in breast cancer
    J G Klijn
    Department of Medical Oncology, Rotterdam Cancer Institute, Dr Daniel den Hoed Kliniek, The Netherlands
    Acta Oncol 35:30-7. 1996
    ..Future studies on treatment of all stages of disease will increasingly focus on promising combined treatment modalities...
  38. pmc Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin
    A W Oosten
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Sarcoma 2009:348910. 2009
    ..If our observations are confirmed in other series, they would suggest that studies performed in STS patients should not only stratify for histological subtype but also for uterine versus non-uterine LMS and for gender...
  39. doi request reprint Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline
    F Y F L De Vos
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    Crit Rev Oncol Hematol 84:252-60. 2012
    ....
  40. ncbi request reprint Clinical experience with venlafaxine in the treatment of hot flushes in women with a history of breast cancer
    A R Van Gool
    Department of Psychiatry, Erasmus Medical Centre Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Neth J Med 63:175-8. 2005
    ..To obtain practical experience with venlafaxine for hot flushes in breast cancer patients and incorporate this in a treatment protocol...
  41. ncbi request reprint Microsatellite instability in a pleomorphic rhabdomyosarcoma in a patient with hereditary non-polyposis colorectal cancer
    M A den Bakker
    Departments of Pathology and Medical Oncology, Erasmus MC Daniel den Hoed, Rotterdam, The Netherlands
    Histopathology 43:297-9. 2003
    ..To describe the rare occurrence of a pleomorphic sarcoma with microsatellite instability in a patient with hereditary non-polyposis colorectal cancer (HNPCC)...
  42. ncbi request reprint Psychological distress and breast self-examination frequency in women at increased risk for hereditary or familial breast cancer
    S Van Dooren
    Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
    Community Genet 6:235-41. 2003
    ..Surveillance consists of biannual physical examination, annual mammography, annual MRI and monthly breast self-examination (BSE)...
  43. ncbi request reprint Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer
    C H Smorenburg
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 39:196-202. 2003
    ..The clinical relevance of these observations with respect to toxicity profiles and antitumour efficacy requires further evaluation...
  44. doi request reprint GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design
    Jaap Verweij
    Erasmus University Medical Center, Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    Adv Exp Med Biol 610:144-54. 2008
  45. ncbi request reprint Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients
    Mieke Kriege
    Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 111:303-11. 2008
    ..Data on distant disease-free interval (DDFI) and the localization of the first distant metastasis (DM) in BRCA1- and BRCA2-associated breast cancer (BC) patients are as yet scarcely available...
  46. ncbi request reprint The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas
    Metin Tascilar
    Department of Medical Oncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075EA Rotterdam, The Netherlands
    Oncologist 12:1351-60. 2007
    ..Furthermore, this review focuses on the anticipated growing role of ifosfamide in the development of new treatment strategies...
  47. ncbi request reprint A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone
    Vibeke Kuenen-Boumeester
    Department of Pathology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Hum Pathol 35:629-32. 2004
    ..Surprisingly, at that time an occult breast carcinoma was identified to be the origin of the 2 metastatic locations as confirmed by molecular analysis. Eventually the patient could be treated accordingly...
  48. ncbi request reprint Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study
    Iris van Oostrom
    Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
    J Clin Oncol 21:3867-74. 2003
    ..To explore long-term psychosocial consequences of carrying a BRCA1/2 mutation and to identify possible risk factors for long-term psychological distress...
  49. ncbi request reprint Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing
    Litanja Lodder
    Department of Medical Psychology and Psychotherapy, Erasmus University, Rotterdam Netherlands Institute for Health Sciences, The Netherlands
    Am J Med Genet A 119:266-72. 2003
    ..However, generalization of these results to women who neither underwent the test nor participated in a surveillance program should be considered with caution...
  50. ncbi request reprint Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation
    Hanne Meijers-Heijboer
    Rotterdam Family Cancer Center, Department of Clinical Genetics, The Netherlands
    J Clin Oncol 21:1675-81. 2003
    ..To analyze the use of genetic testing, prophylactic mastectomy, and oophorectomy among women with breast and/or ovarian cancer from families with a BRCA1 or BRCA2 mutation...
  51. ncbi request reprint One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery)
    Litanja N Lodder
    Department of Medical Psychology, Erasmus University Rotterdam, Netherlands Institute for Health Sciences
    Breast Cancer Res Treat 73:97-112. 2002
    ..This might explain, why most women who underwent prophylactic mastectomy were satisfied with this decision, despite a perceived negative impact on body image, the intimate relationship and physical wellbeing...
  52. ncbi request reprint Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?
    Cecile T M Brekelmans
    Lancet Oncol 7:191-3. 2006
  53. ncbi request reprint Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment
    Stefan Sleijfer
    Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Oncologist 12:719-26. 2007
    ....
  54. ncbi request reprint Gynaecological sarcomas
    Stefan Sleijfer
    Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Curr Opin Oncol 19:492-6. 2007
    ..To review gynaecological sarcomas, their management and future perspectives...
  55. ncbi request reprint Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care
    Stefan Sleijfer
    Department of Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Oncologist 10:833-41. 2005
    ..This review also focuses on these and other strategies that will hopefully lead to better out comes in this disease entity in the near future...
  56. ncbi request reprint Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study
    Peter Nieboer
    University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Clin Oncol 23:8296-304. 2005
    ....
  57. ncbi request reprint Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women
    Paula J C Bresser
    Department of Medical Psychology, The Daniel den Hoed Cancer Center, Erasmus Medical Center, Rotterdam, The Netherlands
    Plast Reconstr Surg 117:1675-82; discussion 1683-4. 2006
    ..In the present follow-up study, the authors assess satisfaction with prophylactic mastectomy and breast reconstruction and its impact on sexual relationships...
  58. ncbi request reprint Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of
    Marijke Bontenbal
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:7081-8. 2005
    ..To compare the efficacy and safety of doxorubicin and docetaxel (AT) with fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line chemotherapy for metastatic breast cancer (MBC)...
  59. ncbi request reprint Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer
    Mieke Kriege
    Family Cancer Clinic, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Breast Cancer Res Treat 100:109-19. 2006
    ..In the current subsequent study we investigated whether these results are influenced by age, a BRCA1/2 mutation, menopausal status and breast density...
  60. ncbi request reprint Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress
    Iris van Oostrom
    Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, The
    Patient Educ Couns 65:58-68. 2007
    ..To study differences between individuals opting for genetic cancer susceptibility testing of a known familial BRCA1/2 and HNPCC related germline mutation...
  61. ncbi request reprint A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships
    Iris van Oostrom
    Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Westzeedijk 114, 3016 AH Rotterdam, The Netherlands
    Psychooncology 16:320-8. 2007
    ..Open communication between relatives should be stimulated because a lack of open communication may be an important determinant of familial adverse effects...
  62. ncbi request reprint Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing
    Iris van Oostrom
    Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Westzeedijk 112 114, 3016 AH, Rotterdam, The Netherlands
    Eur J Cancer 43:71-7. 2007
    ..Individuals who may benefit from additional support may be identified before result disclosure using a short instrument assessing the relevant aspects...
  63. ncbi request reprint Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases
    Serge C L M Cremers
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 20:1543-7. 2005
    ..Relationships between skeletal retention of pamidronate and rate of bone resorption are complex and depend on previous treatment and the total amount of retained bisphosphonate...
  64. ncbi request reprint Practical aspects of managing gastrointestinal stromal tumors
    Stefan Sleijfer
    Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Clin Colorectal Cancer 6:S18-23. 2006
    ..This review addresses several aspects of the current management of GIST as well as some novel developments...
  65. ncbi request reprint Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer
    Silvia van Dooren
    Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
    Eur J Cancer 41:1416-25. 2005
    ..The course of general distress differed significantly for women closely involved in a sister's BC-process. These more vulnerable subgroups may be in need of extra counselling and care...
  66. ncbi request reprint Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer
    Paul A M Meeuwissen
    Family Cancer Clinic, The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Erasmus University Medical Centre Rotterdam, Room H585, Dr Molewaterplein 40, 3000 CC Rotterdam, The Netherlands
    Gynecol Oncol 97:476-82. 2005
    ..Women at high risk of ovarian cancer are currently offered two options: either surveillance or prophylactic bilateral salpingo-oophorectomy. The efficacy and outcome of surveillance remain unclear...
  67. ncbi request reprint The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for hereditary breast cancer
    Silvia van Dooren
    Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
    Breast Cancer Res Treat 89:75-80. 2005
    ..Being at hereditary risk of breast cancer (BC) may lead to elevated levels of distress because of the impact of the BC-process in relatives...
  68. ncbi request reprint The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective study
    Iris van Oostrom
    Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Psychooncology 16:1121-9. 2007
    ..Identifying unhelpful representations and cognitive restructuring may be appropriate interventions to help distressed individuals undergoing genetic susceptibility testing for a BRCA1/2 or a HNPCC-related mutation...
  69. ncbi request reprint Psychological distress in women at increased risk for breast cancer: the role of risk perception
    Silvia van Dooren
    Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
    Eur J Cancer 40:2056-63. 2004
    ..This knowledge should be used during surveillance appointments in order to improve and individualise support for these women...
  70. ncbi request reprint Targeted therapy: ready for prime time?
    Caroline Seynaeve
    Dept of Medical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Cancer Treat Res 120:1-15. 2004